54 results about "Adenosine monophosphate" patented technology

The invention discloses a 3 '-phosphoadenosine-5'-phosphoryl sulfate synthetase mutant and an application of the 3 '-phosphoadenosine-5'-phosphoryl sulfate synthetase mutant. Compared with a wild enzyme amino acid sequence as shown in SEQ ID NO.1, the amino acid sequence of the 3 '-adenosine-5'-phosphoryl sulfate synthetase mutant has one or two mutations in the 101 site, the 207 site and the 560 site; preferably, phenylalanine at the 101 site is mutated into tryptophan; cysteine at the 207th site is mutated into glycine; phenylalanine at the 560th site is mutated into tryptophan. The invention also provides a synthesis method and application of the 3 '-adenosine-5'-phosphoryl sulfuric acid. The APS intermediate product inhibition effect of hPAPSS1 is relieved through a point mutation technology, the substrate affinity of hPAPSS1 to ATP is improved, and a mutant enzyme with a high PAPS conversion rate is obtained; and the bifunctional enzyme hPAPSS1 is synthesized by heterologous expression of PAPS in escherichia coli, so that the acquisition of the enzyme is simplified, and the synthesis efficiency of PAPS is improved.

The invention relates to the technical field of biological medicine, in particular to a novel polypeptide and application thereof in medicine for treating cardiovascular diseases. The polypeptide has a unique amino acid sequence, and is composed of an amino acid sequence of SEQ. NO: 1: Leu-Asn-Pro-Thr-Glu (LNPTG), an amino acid sequence of SEQ. NO: 2: Val-His-Met-Arg-Tyr (VHMRY), and the like. The polypeptide has a unique amino acid sequence, and provides a new way for the treatment of cardiovascular diseases by adjusting the activity of AMPK and improving the cardiovascular function.

This application discloses a cyclic GMP-AMP synthase mutant. Compared to the wild-type cyclic GMP-AMP synthase shown in SEQ ID NO.1, the amino acid sequence of the cyclic GMP-AMP synthase mutant has any one of the following mutations: L377M or H437T / S434T. Specifically, the amino acid sequence of the L377M mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.4, and the amino acid sequence of the H437T / S434T mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.9. The cGAS mutant of this application exhibits four times the activity of the wild-type. The preparation method uses readily available and economical raw materials, is simple to operate, environmentally friendly, and pollution-free, with high synthesis efficiency, making it suitable for industrial development.

The invention discloses an AMP sulfating enzyme mutant for producing adenosine phosphoryl sulfuric acid and application, and belongs to the technical field of biological engineering. According to the invention, AMP is used as a raw material, and AMP sulfating enzymes BtaAPSST M2 and PcAPSK are used for biosynthesis of PAPS. Under the catalysis of 10 g / L of BtaAPSST M2 wet thallus and 20 g / L of PcAPSK wet thallus, the conversion rate of PAPS is 70.59%. Compared with the existing ATP sulfating enzyme capable of catalyzing ATP to generate APS, the ATP sulfating enzyme disclosed by the invention is lower in cost and equivalent in conversion rate. Wherein the PAPS yield of the BtaAPSST M2 is two times that of a wild enzyme, and the industrial process of producing the PAPS by a microbial synthesis method is accelerated.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for distinguishing hypertrophic cardiomyopathy and left ventricular hypertrophy and application. The application analyzes the metabolome of hypertrophic cardiomyopathy (HCM) patients, left ventricular hypertrophy (LVH) patients caused by non-hypertrophic cardiomyopathy and healthy people, finds that carnitine C16:2, carnitine C14:0, carnitine C16:0, carnitine C18:0 and carnitine C18:1 are differentially expressed in HCM patients and LVH patients, pyridoxine phosphate, ito acid, adenosine monophosphate, adenosine diphosphate and adenosine triphosphate are differentially expressed in HCM patients and healthy people, lysine base, methyl glutamic acid, acetyl proline, malate semialdehyde and citramalate are differentially expressed in LVH patients and healthy people, and ROC curve analysis shows excellent prediction effect, strong specificity and high sensitivity.

Disclosed in the invention are a type of compounds having activity of activating 5′-adenosine monophosphate-activated protein kinase (AMPK), a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for reducing fatty acid synthesis, for inhibiting triglyceride and cholesterol synthesis, for preventing and / or treating obesity and type II diabetes, for preventing and / or treating tumor, for preventing and / or treating Parkinson's disease, for preventing and / or treating Alzheimer's disease or for prolonging the lifespan of mammals:

The present application belongs to the technical field of biological fermentation and discloses a process for the production of L-histidine by biological fermentation. It comprises the following steps: inoculating a seed solution of Escherichia coli into a fermenter containing a fermentation medium at a culture temperature of 35-37°C, maintaining the reducing sugar content at 46 g / L by adding a glucose solution containing adenosine monophosphate in fed-batch increments, stopping the addition of the glucose solution 4 hours before the end of fermentation, maintaining the pH in the fermenter at 6.9-7.1 by adding ammonia solution in fed-batch increments, and adding an antifoaming agent to control foaming, with the fermentation time being 40-50 hours, thereby obtaining an L-histidine fermentation solution.The process according to the present application exhibits high fermentation efficiency and low production costs and is suitable for industrial production.

The invention provides a method for simultaneously determining various flavor nucleotides in a livestock and poultry meat product and application, and the method comprises the following steps: freeze-drying the livestock and poultry meat product, and then preparing the freeze-dried livestock and poultry meat product into a test solution; measuring the contents of CMP (cytidylic acid), ATP (adenosine triphosphate), GMP (guanine monophosphate), IMP (inosinic acid), ADP (adenosine diphosphate), Hy (hypoxanthine), AMP (adenosine monophosphate) and IN (inosine) in the test solution by adopting HPLC (high performance liquid chromatography); in HPLC, a mobile phase A is a phosphate buffer solution with the volume concentration of 95%, a mobile phase B is methanol with the volume concentration of 5%, gradient elution is carried out, and the gradient elution condition is 0-11 min, 99% phosphate buffer solution and 1% methanol; when 12 min, 80% phosphate buffer solution and 20% methanol are added, and the conditions are maintained for 6-7 min; the phosphate buffer solution is heated to 99% within 2 minutes, and then the temperature is kept for 8-10 minutes.

Cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase (cGAS) is an enzyme sensor of double-stranded DNA (dsDNA) that serves to trigger activation of the cGAS-stimulator of interferon genes (STING) pathway. The inhibition of cGAS with Cladophorol A is described herein.

The invention discloses an application of lactobacillus delbrueckii subsp. Lactis ABSN20244504 and a metagen thereof in preparation of a product for inhibiting skin light injury, and relates to the technical field of microorganisms, the preservation number of the strain is CGMCC No.34743, and the strain is separated from traditional fermented yak yoghourt in the Alba plateau in Sichuan of China and has good capability of tolerating artificial gastric acid and cholate in vitro. The invention also discloses an application of the strain and the inactivated metagen thereof in preparation of a product for inhibiting skin light injury. Animal experiments show that the mouse skin injury induced by ultraviolet B can be obviously relieved whether the viable bacteria of the strain are orally taken or locally smeared with inactivated postbiotics of the strain, and the action mechanism of the strain is related to oxidative stress relieving, inflammatory reaction inhibiting, AMPK (adenosine monophosphate kinase) adjusting and other related signal channels. The invention provides a new strain resource and an application strategy for developing a novel oral probiotic preparation and an external cosmetic for preventing and repairing skin light injury.

The invention relates to the technical field of biological medicines, and particularly discloses application of adenosine monophosphate in preparation of a medicine for treating osteoarthritis. Cell tests show that the adenosine monophosphate solution has an inhibition effect on cartilage cell activity; animal model tests show that the adenosine monophosphate normal saline solution can remarkably relieve the cartilage injury degree of osteoarthritis mice and relieve osteoarthritis, and a new way is provided for improvement of osteoarthritis conditions. The chemical structural formula of adenosine monophosphate is shown in the specification.

The present invention belongs to the technical field of preparing functional materials for molecular recognition, adsorption and separation, and discloses a method for preparing a hydrophilic dual-receptor MOFs nanosheet surface imprinted adsorbent and its application in the selective separation of adenosine monophosphate. The present invention targets the structural characteristics of a typical nucleoside compound adenosine monophosphate (AMP) molecule, designs and synthesizes Zr-MOFs nanosheets coordinated with its specific metal ion as a matrix material, and uses 5-(2-methoxyvinyl)-2′-deoxyuridine (AcrU) as a functional monomer that undergoes specific base complementary pairing. The arrangement and orientation of the template molecules are precisely fixed through an ordered assembly strategy. Finally, the large number of double bonds modified on the surface of the Zr-MOFs nanosheets and a hydrophilic cross-linking agent are utilized to photoinitiate the construction of a stable hydrophilic dual-receptor MOFs nanosheet surface imprinted adsorbent (D-MIPs), thereby enhancing the recognition and separation effect of nucleoside compounds and achieving the selective separation and enrichment of nucleoside compounds such as AMP in biological samples such as urine and blood.

The application provides a uridine monophosphate specific glycoside hydrolase and application thereof in biosynthetic synthesis of pseudouridine. Nmygdh The function of the gene is verified by in-vitro enzyme activity experiment Nmygdh The recombinant protein has broad-spectrum and high-efficiency catalytic activity, and can efficiently catalyze the hydrolysis of glycosidic bonds in various nucleotides, such as uridine monophosphate (UMP), guanosine monophosphate (GMP), adenosine monophosphate (AMP) and cytidine monophosphate (CMP), and the activity of uridine monophosphate is the strongest. The application uses the protein to efficiently hydrolyze uridine monophosphate to obtain two substrates of pseudouridine, i.e. uracil and 5'-phosphoribose, and realizes the atom-economical and efficient biosynthetic synthesis of pseudouridine by combining the cascade reaction of pseudouridine glycosidase EcPsuG and dephosphorylase EcYjjG.

The invention belongs to the technical field of biological detection and analysis, and particularly relates to an adenosine phosphate photoaffinity probe as well as a preparation method and application thereof. The probe comprises an AMP-N (adenosine monophosphate-N) photoaffinity probe, an ADP-N (adenosine monophosphate-N) photoaffinity probe and an ATP-N (adenosine monophosphate-N) photoaffinity probe, the phosphoric acid part of adenosine monophosphate is modified with a photoaffinity group diaziridine with a small volume and alkynyl capable of carrying out a biological orthogonal reaction, and a connecting bond capable of cracking under an acidic condition is designed between adenosine monophosphate and a photoreactive group. The probe is high in stability and good in marking efficiency, can specifically mark the adenosine phosphate binding protein and identify the binding site of the adenosine phosphate binding protein, is suitable for screening, functional research and affinity analysis of the adenosine phosphate binding protein and discovery and verification of related drug targets, and has a wide application prospect.

The application discloses a cyclic GMP-AMP synthetase mutant and a method for preparing 2',3'-cyclic guanosine monophosphate-adenosine monophosphate by using the cyclic GMP-AMP synthetase mutant, wherein the amino acid sequence of the cyclic GMP-AMP synthetase mutant has any one of the following mutations: P361A, L377M, K432R, S221Y / F357L / I496V, S221L / Y248F / K432H / S434T, F357L / P361A / L377M / S434T, F357L / P361A / S434T / H437T or H437T / S434T, compared with a wild type as shown in SEQ ID NO. 1. The activity of the cGAS mutant of the application can reach 4 times of the wild type, raw materials of the preparation method are economical and easy to obtain, the operation is simple, green, environment-friendly, pollution-free, the synthesis efficiency is high, and industrial development is easy.

This method and composition involves oral administration of a low dose of D-ribose to enhance adenosine monophosphate-activated protein kinase (AMPK) activity in both exercising and sedentary mammals, improve mitochondrial-related oxidative metabolic parameters, and thereby promote overall metabolic health in mammals.

This invention provides a kit for the simultaneous detection of nine flavor nucleotides in livestock and poultry products. The flavor nucleotides are cytidine monophosphate, uridine monophosphate, guanylic acid, inosine monophosphate, adenosine monophosphate, hypoxanthine, inosine, adenosine diphosphate, and adenosine triphosphate. The kit includes: a high-concentration extraction reagent, a standard curve solution, a high-concentration phosphate buffer solution, pH adjustment solution A, and pH adjustment solution B. The high-concentration extraction reagent is perchloric acid; the standard curve solution is a mixed solution of the nine flavor nucleotides; the high-concentration phosphate buffer solution is a solution of potassium dihydrogen phosphate and dipotassium hydrogen phosphate; pH adjustment solution A is sodium hydroxide; and pH adjustment solution B is phosphate. This invention also provides a method for the simultaneous detection of the nine flavor nucleotides using the above kit. This invention enables the simultaneous determination of the content of nine flavor nucleotides in livestock and poultry products. The method is simple, rapid, accurate, and sensitive, and can be used for batch determination, showing good prospects for practical application.

The present disclosure relates to methods and compositions for editing an AMPK polynucleotide encoding an AMPK protein. The disclosure also relates to methods and compositions for modulating activity of an AMPK protein, for promoting activation of an AMPK protein, for repairing function of a pathogenic AMPK protein, and methods for regulating energy homeostasis and / or for treating or preventing an AMPK-associated disease or condition in a subject.

The present invention discloses a steel bar rust inhibitor for use in complex chloride environments, as well as its preparation and use methods. The steel bar rust inhibitor comprises a solvent and a solute dissolved therein, wherein the solvent is hydrolase-free double-distilled water with a pH greater than 6.0; the solute comprises, by mass percentage, 80%-90% DAP dry powder and 10%-20% PVA powder; wherein the DAP is prepared by grafting adenosine monophosphate, adenosine diphosphate, and adenosine triphosphate onto a nucleoside phosphorous acid activated intermediate. Compared with existing rust inhibitors, the present invention utilizes a more simplified synthesis method, which, while ensuring significant rust inhibition, avoids the limitations of the use environment and the agglomeration phenomenon caused by excessive molecular weight.

The present application relates to the technical field of enzyme, in particular to a mutant of BsBacD enzyme, an enzyme composition and a preparation method of tyrosine dipeptide. The present application firstly rationally designs the BsBacD enzyme, then replaces ADP (adenosine diphosphate or its salt) with relatively cheap ATP (adenosine triphosphate or its salt) or even cheaper AMP (adenosine monophosphate or its salt), and introduces polyphosphate kinase ChPPK2 which can regenerate ATP with AMP as a substrate to synthesize tyrosine dipeptide, and optimizes reaction pH, magnesium chloride concentration and substrate tyrosine concentration and other parameters, and develops a low-cost and high-efficiency enzyme synthesis process of three kinds of tyrosine dipeptides, such as propyl tyrosine dipeptide, glycosyl tyrosine dipeptide and silk tyrosine dipeptide.

The invention provides application of herpetonol in preparation of a medicine for treating or / and preventing fatty liver diseases. According to the invention, through a mouse model established by high fat diet (HFD) and a cell model induced by free fatty acid (FFA), the influence of herpetolol (HPO) on metabolic dysfunction related fatty liver disease (MASLD) is researched. In addition, through a drug affinity reaction target spot stability experiment (DARTS) and a cell thermal displacement experiment (CETSA), a key target spot of the action of the HPO and an action mechanism of the HPO are identified. Research finds that in an MASLD mouse model, the treatment of the hernol (HPO) significantly alleviates the lipid accumulation and inflammatory infiltration of the liver, and reveals that the hernol directly targets an adiponectin receptor 1 (ADIPOR1), up-regulates the expression of the ADIPOR1, activates an adenylate activated protein kinase (AMPK) pathway and further inhibits the nucleation regulation of sterol regulatory element binding protein 1c (SREBP-1c), thereby providing a potential direction for the treatment strategy of the MASLD.

The invention discloses a method for visually detecting various phosphates, which comprises the following steps: firstly, synthesizing three MOF (Metal Organic Framework) nano-enzymes, namely PCN-222 (Fe), PCN-223 (Fe) and PCN-224 (Fe) with peroxidase-like activity, catalyzing a colorless substrate 3, 3 ', 5, 5'-tetramethyl benzidine (TMB) into oxTMB in a blue oxidation state by the three MOF nano-enzymes in the presence of H2O2, and generating remarkable colorimetric response; then, the five phosphates, namely ATP (adenosine triphosphate), ADP (adenosine diphosphate), AMP (adenosine monophosphate), PPi (pyrophosphoric acid) and Pi (inorganic phosphate), are simultaneously distinguished and detected by utilizing the principle that different phosphates have different regulation degrees on the peroxidase-like activity of the MOF nano-enzyme. In combination with a smartphone application program 'ColorMax', real-time visual analysis of phosphate is realized, and an efficient and convenient method is provided for distinguishing and detecting different phosphates.

The application provides an anti-osteoarthritis nanometer radionuclide gel and a preparation method and application thereof 177 Lu and adenosine monophosphate coordination self-assembly 177 Lu-labeled metal organic framework, chitosan forms a temperature-sensitive gel in the case of glycerophosphate sodium as a crosslinking agent. The temperature-sensitive gel encapsulates 177 Lu-labeled metal organic framework not only helps to prolong the retention time of radionuclide in the local joint cavity, and by utilizing the temperature response performance of the high molecular material in the temperature-sensitive gel, a semi-solid gel is formed in situ in the joint, which not only has good viscoelasticity, lubrication and buffering of the joint, but also can play a barrier effect to prevent the diffusion of inflammatory substances in the joint cavity, and the degradation components of chitosan can stimulate the production of collagen and glycosaminoglycan of chondrocytes, and play a role in protecting and repairing cartilage. Therefore, the nanometer radionuclide gel is an excellent RSO drug delivery system, and has good biocompatibility and degradability.

The invention discloses application of sodium bicarbonate in preparation of a medicine for enhancing anti-tumor immunity. The molecular formula of the sodium bicarbonate is NaHCO3. Sodium bicarbonate can enhance natural immunity and acquired immunity of tumor resistance, and is characterized by including but not limited to activation of a cyclic guanylate-adenylate synthetase (cGAS)-interferon gene stimulating factor (cGAS-STING) signal channel in tumor cells, promotion of infiltration of immune cells in tumors and enhancement of the antitumor efficacy of the immune checkpoint inhibitor.

The invention discloses a panax notoginseng saponins oral instant film preparation as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The panax notoginseng saponins oral instant film preparation is prepared from the following components: panax notoginseng saponins, a taste masking agent, a film forming material, a plasticizer, a disintegrating agent and a flavoring agent, the taste masking agent comprises chitosan and sodium tripolyphosphate; the flavoring agent comprises one or more of adenosine monophosphate, phosphatidic acid and glutamic acid; the mass ratio of the chitosan to the sodium tripolyphosphate is (3.5: 1)-(5: 1). The panax notoginseng total saponin oral instant film preparation is good in taste, good in mixing uniformity, uniform in thickness, good in toughness and good in appearance, and can meet the medication requirements of cardiovascular and cerebrovascular patients, especially cardiovascular and cerebrovascular patients with dysphagia.

The present invention relates to compounds of Formulas I to V and Ib to Vb, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP).

The invention discloses application of polyphosphate kinase BsPPK in synthesis of ATP (adenosine triphosphate). The amino acid sequence of the polyphosphate kinase BsPPK is as shown in SEQ ID NO. 1. In specific application, adenosine diphosphate or adenosine monophosphate is used as a phosphate receptor, polyphosphate is used as a phosphoric acid donor, and ATP is synthesized under the action of polyphosphate kinase BsPPK. The polyphosphate is selected from tripolyphosphate or hexametaphosphate. The invention also discloses an application of the polyphosphate kinase BsPPK in the synthesis of uridine diphosphate-galactose, and an application of the polyphosphate kinase BsPPK in the synthesis of lactosyl-N-tetrasaccharide. According to the method, the ATP is synthesized and regenerated by utilizing the polyphosphate kinase BsPPK, so that the reaction cost of UDP-Gal and LNT in-vitro synthesis routes is greatly reduced. The method has important significance on ATP regeneration and synthesis of UDP-Gal and galactosyl lactose derivatives, and has a wide application prospect.

The invention relates to the technical field of ischemic injury treatment, in particular to a method for regulating oxidative stress in ischemic injury by a GDF-15 mediated AMPK signal pathway, which comprises the following steps: inoculating myocardial cell deficiency into a culture medium in groups to form a normal group, an anoxia group and an anoxia supplement group; constructing an influence relation curve according to the GDF-15 expression quantity and the AMPK phosphorylation level so as to determine the difference degree and the difference significance, and determining the direct regulation weight of the GDF-15 on the AMPK pathway according to the difference degree and the difference significance; determining the correlation degree of the mitochondrial membrane potential and the oxidative stress in the sample to be detected, and determining the indirect regulation weight of the GDF-15 on the oxidative stress based on the correlation degree, the mitochondrial membrane potential, the ROS content and the GDF-15 expression quantity; determining the direct regulation contribution rate of the GDF-15 to the AMPK pathway based on the direct regulation weight and the indirect regulation weight; the invention discloses a complex regulation and control relationship between the GDF-15 in ischemic injury and an AMPK (Adenosine Monophosphate Protein Kinase) pathway as well as oxidative stress.

This invention provides peptides with anti-obesity and / or anti-diabetic activity, composed of the amino acid sequence of Sequence 1 or Sequence 2. These peptides inhibit fat accumulation, reduce the size of adipocytes, and increase the expression of phosphorylated hormone-sensitive lipase, adenosine monophosphate-activated protein kinase-α1, and comparative gene recognition-58 (CGM-58), which are lipolysis factors, thereby breaking down accumulated fat. This not only exhibits excellent anti-obesity effects but also effectively reduces blood glucose levels, increasing the expression of adiponectin and adenosine monophosphate-activated protein kinase (CGM-58), which improve insulin resistance; increasing the expression of glucose transporter protein 4 (a glucose transport channel); and increasing the expression of insulin receptor substrate-1 (an insulin receptor signaling protein), thus exhibiting excellent effects against diabetes. The peptides of this invention can be effectively used in the prevention or treatment of obesity and / or diabetes.

The invention relates to the technical field of biomedicine, and aims to solve the problems of poor drug permeability, drug resistance, drug toxicity, high surgical risk, infection recurrence, donor tissue shortage and the like of prevention and treatment means of fungal keratitis. The invention provides application of a metabolic marker in preparation of a product for diagnosing, preventing or treating fungal keratitis and a screening method of the metabolic marker. The metabolic marker is at least one of adenosine, adenosine monophosphate and uric acid. In fungal cornea, adenosine and adenosine monophosphate are reduced, and uric acid is increased. According to the invention, three differential metabolites are screened based on the combination of non-targeted metabonomics and targeted mass spectrometry detection, and the provided purine metabolic pathway regulation and the level of the three metabolites can be used for diagnosis of fungal keratitis patients and research and development of new therapeutic targets.